Business
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), being held on December 1-4, 2025 in S
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA.","length":513,"tagName":"p"},{"type":"text","content":"The new analyses add to the growing body of clinical, biomarker, and imaging evidence supporting XPro1595’s mechanism of selectively neutralizing soluble TNF (sTNF). The data further validate the Company’s strategy of targeting inflammation-driven AD, a large, underserved subset representing a significant unmet need and potential commercial opportunity.","length":355,"tagName":"p"},{"type":"text","content":"New Grey Matter Signals Strengthen Biological Rationale for XPro1595","length":68,"tagName":"p"},{"type":"text","content":"Using PerpPD+, a next-generation MRI imaging analysis that quantifies the diffusion components of water molecules that are perpendicular to the cortical gray matter’s minicolumns in the brain (PerpDP+, from Oxford Brain Diagnostics), investigators observed a trend towards slowed neurodegeneration progression in patients receiving XPro1595. These analyses focused on participants with early AD and high inflammatory burden (ADi), including the dose-compliant subgroup.","length":469,"tagName":"p"},{"type":"text","content":"The PerpPD+ findings suggest attenuated increases in cortical disarray, an imaging hallmark associated with neurodegeneration. These results reinforce previously reported directional improvements across biologica...